Frieda Wiley, PharmD

Novel drugs, value-based contracting, biosimilars, and regulatory activity addressing costs will be among the hot button issues in the coming year.

Payer education, evidence critical to providing cost-effective, beneficial treatment in pharmacogenetics.

What to expect for these high-dollar drugs.